Portfolio Companies

Portfolio Companies

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

: (NASDAQ: FOLD)

Cranbury, NJ
Developing small molecule, orally active drugs to treat lysosomal storage disorders using pharmacological chaperones to selectively bind and "rescue" misfolded target proteins

: Baltimore, MD
Developing arginase inhibitors for vascular and pulmonary conditions

: Ewing, NJ
Advanced computational fragment-based drug design technology for lead generation and optimization

: Pittsboro, NC
Uses a Lemna-based manufacturing system to produce recombinant therapeutic proteins, targeting infectious diseases, thrombosis, and autoimmune diseases

: King of Prussia, PA
Uses a proprietary protein engineering platform and a modified form of transferrin to enhance half life, efficacy, and safety of proteins; initially targeting diabetes
Acquired by Pfizer in February 2007

: Princeton, NJ
Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers

: Philadelphia, PA
Uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases
ACQUIRED BY CYPRESS BIOSCIENCE IN FEBRUARY 2009

: Chapel Hill, NC
Developing drugs for difficult-to-treat and drug-resistant bacterial infections, including community-acquired bacterial pneumonia and MRSA infections

: Conshohocken, PA
Uses Hepatocyte Directed Vesicles to deliver insulin for diabetes treatment

: (NASDAQ: DSCO)

Warrington, PA
Developing a synthetic lung surfactant to aid lung development in premature infants

: Bedminster, NJ
Specialty pharma company focused on the acute care setting, treating conditions in cardiology, thrombolytic, and oncology supportive care areas

: Berwyn, PA
Developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA
Acquired by YM Biosciences in May 2006

: West Conshohocken, PA
Targeting serotonin receptors to initiate apoptosis to treat multiple myeloma and psoriasis

: Pittsburgh, PA
Specialty pharmaceutical distributor, focused on high-cost injectables and infusibles that require special handling and strict adherence to prescribed treatment protocols
Acquired by Walgreen Co. in July 2006

: Malvern, PA
Developing novel oncolytic viruses to treat cancer

: Malvern, PA
Developing and commercializing Transcranial Magnetic Stimulation, a noninvasive medical technology, to treat psychiatric and neurological disorders

: Bristol, PA
Development of a proprietary and patented drug/device technology, delivering gaseous nitric oxide for the treatment of chronic wounds, skin infections and psoriasis

: Conshohocken, PA
Specialty pharma company developing innovative products for the treatment of neurologic and psychiatric diseases

: New Haven, CT
Developing therapeutics and diagnostics based on Complement Factor H (CFH) research to treat for the dry form of age related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN-II)

: Pittsburgh, PA
Personalized diagnostics enabling customized and predictive treatment decisions for cancer patients

: Malvern, PA
Developing small molecule antibiotics to address increasing bacterial resistance and chronic or recurrent infections
Acquired by Novartis AG in July 2008

: Morrisville, NC and Basking Ridge, NJ
Developing antidote-controlled antithrombotics via rational design of drug-antidote pairs, using modified RNA-based aptamers

: Bedford, MA
Developing and commercializing automated rapid testing to detect microbiological contamination in the manufacture of pharmaceutical and personal care products.

: Saddle Brook, NJ
Commercializing consumer products for female sexual health, including lead product Zestra®

: Glen Burnie, MD
Provides at-home diagnostic testing of obstructive sleep apnea (OSA) as an alternative to in-laboratory sleep studies

: Horsham, PA
Emerging growth services company revolutionizing the way pharmaceutical companies apply marketing information to their operations

: Philadelphia, PA
Developing an oral formulation of calcitonin for the treatment of osteoporosis

: Morrisville, NC
Clinical stage company developing a novel, office-based medical device to treat dry eye syndrome

: East Norriton, PA
Developing human tissues and organs, derived from a patient's own cells, initially treating spina bifida and spinal cord injury with the neo-bladder

: Malvern, PA
Developing novel, targeted drugs to treat cancer by regulating the apoptosis (programmed cell death) pathway

: Monmouth Jct., NJ
Developing inhaled therapeutics to treat chronic respiratory infections

: Durham, NC
Commercializing revolutionary medical device that enables minimally invasive single-incision, single-port surgery

: Durham, NC
Developing unique small molecule therapeutics, using its proprietary chemistry platform; initially targeting GI motility disorders